Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06081673
PHASE2

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

View on ClinicalTrials.gov

Summary

This study aims to observe and explore the efficacy and safety of Penpulimab combined with chemotherapy for neoadjuvant and adjuvant therapy in patients with resectable head and neck squamous cell carcinoma.

Official title: A Phase II Clinical Study of Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable Head and Neck Squamous Cell Carcinoma

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

72

Start Date

2023-10-30

Completion Date

2026-10-30

Last Updated

2023-10-13

Healthy Volunteers

No

Interventions

DRUG

Penpulimab injection

Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2); 200mg,D1, IV(21 days/cycle).

DRUG

cisplatin

Cisplatin :75mg/m2, D1, IV(21 days/cycle)

DRUG

albumin-paclitaxel

albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)

Locations (1)

Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China